Everything about Tyrosinase-IN-12
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre analyze To judge numerous intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Principal demo aims were being To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis peo